Engage Therapeutics CEO and Founder Greg Mayes selected to present at the 2020 Emerging MedTech Summit.

Engage Therapeutics Announces Data from Phase 2a, Proof-of-concept Study of Staccato Alprazolam to Suppress Seizures in Patients with Epilepsy Published in Epilepsia
July 9, 2019
Proof of Concept trial results for Staccato Alprazolam has neurology community cautiously optimistic
August 14, 2019


Greg Mayes, Engage Therapeutics’ CEO and Founder, will join other Life Science Intelligence leaders at the Ritz Carlton Laguna Niguel in Dana Point, CA February 18 – 20, 2020 at an event that brings together the top strategists, investors and innovators who are driving the medical technology industry forward.